Precision BioSciences (DTIL) announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application ...

Chronic hepatitis B virus (HBV) infection continues to pose a major global health threat. The virus evades immune responses and antiviral therapies due to the persistence of covalently closed circular ...

The US joins Moldova, Hong Kong, and New Zealand as countries to greenlight the company's Phase I trial of PBGENE-HBV.

David says. At the heart of the mystery that intrigued the researchers lies a key viral gene that encodes for a protein called X. This protein is essential for HBV to establish a productive ...

At the heart of the mystery that intrigued the researchers lies a key viral gene that encodes for the HBV X protein (HBx). This protein is essential for HBV to establish a productive infection in ...

Hepatitis B virus infection remains one of the leading causes of liver disease, including cirrhosis and hepatocellular carcinoma.

His interest in epigenetic regulation in pathogens made HBV an ideal model system for him to explore. At the heart of the mystery that intrigued the researchers lies a key viral gene that encodes ...

Precision BioSciences has reported initial outcomes from the ELIMINATE-B trial of PBGENE-HBV, a gene editing programme for treating chronic Hepatitis B patients who are HBeAg-negative. In cohort ...

ELIMINATE-B Phase 1 dose finding study for chronic Hepatitis B executing on schedule with completion of first dose administration for cohort 1 (n=3 patients) PBGENE-HBV, the first LNP gene editing ...